ZTS logo

ZOETIS INC

ZTSNYSE
πŸ† #334 by market capEarnings Nov 2 Β· PreUS Equity
$397.80β–Ό $21.48 (βˆ’5.40%)
Simulated price
1hβ€”
24hβ–Ό 5.4%
7dβ€”
14dβ€”
30dβ€”
1yβ€”
🏦Market Cap
$31.87B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+1.4%
Slowing
πŸ“ŠGross Margin
71.6%
High
πŸ’΅FCF Margin
24.9%
Strong
βš–οΈP/S Ratio
3.2x
Fair
Otter Score
45
Weak
No chart data available for ZTS.

Trading Snapshot

Day Range
$392.35 – $404.75
52-Week Range
$71.45 – $160.48
Volume
$2.90B
Avg Volume
$2.86B
Shares Outstanding
419.2M
Next Earnings
Oct 8, 2026

Fundamentals Snapshot

Annual Revenue
$9.47B
Last Q Revenue
$2.47B
P/E Ratio
11.6
P/S Ratio
3.2x
EPS (TTM)
$6.08
Dividend Yield
2.92%

Why Investors Own ZTS

  • βœ“High-growth profile β€” revenue up +54.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 60% gross margin and 18% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$9.47Bβ–² +50.6% YoY
Gross Margin (TTM)
59.5%β–² +3.7% YoY
Operating Income (TTM)
$1.13Bβ–² +50.6% YoY
Free Cash Flow (TTM)
$1.74Bβ–² +50.6% YoY

About ZOETIS INC

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
45/100

Analyst Price Target

β“˜
Average Target
$454.16
β–² +14.2% Upside
High Target$496.22
Low Target$400.74
Based on 28 analysts

Latest News & Updates